8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2021

SANARA MEDTECH INC.

(Exact name of registrant as specified in its charter)

Texas	001-39678	59-2219994
(State or other jurisdiction of	(Commission	(IRS Employer
incorporation)	File Number)	Identification No.)

1200 Summit Avenue, Suite 414 Fort Worth, Texas	76102
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (817) 529-2300

(Former name or former address, if changed since last report)

Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	SMTI	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Retirement and Resignation of Principal Executive Officer and Director

On December 22, 2021, Sanara MedTech Inc. (the “Company”) entered into a Retirement Agreement (the “Retirement Agreement”) with J. Michael Carmena, the Company’s Principal Executive Officer, providing for Mr. Carmena’s retirement from the Company. In connection with the Retirement Agreement, Mr. Carmena delivered a letter providing notice of his resignation from his position as Principal Executive Officer of the Company and as a member of the Board of Directors (the “Board”), effective December 31, 2021. Mr. Carmena will continue to be an employee of the Company until January 3, 2022 (the “Retirement Date”). Mr. Carmena’s retirement and resignation is not as a result of any disagreement with the Company or the Board on any matter relating to the Company’s operations, policies or practices.

Under the Retirement Agreement, the Company has agreed to pay Mr. Carmena the following separation payments and benefits, subject to his meeting his obligations under the Retirement Agreement: (i) a one-time cash payment of $75,000, to be paid no later than January 15, 2022, (ii) a restricted stock grant consisting of 3,549 shares of the Company’s common stock, which shall vest on the Retirement Date and (iii) accelerate and waive all forfeiture and vesting provisions related to a restricted stock award previously granted to Mr. Carmena under the Company’s Restated 2014 Omnibus Long Term Incentive Plan, as amended, such that 4,017 shares of restricted stock shall vest on the Retirement Date.

Until two years after the Retirement Date, Mr. Carmena agreed to certain non-competition, non-solicitation and non-disparagement covenants.

The foregoing description of the Retirement Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such document, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Appointment of Director

On December 16, 2021, the Board appointed Eric Tanzberger as a director of the Company, effective January 1, 2022 (the “Effective Date”), to fill the vacancy that will result from Mr. Carmena’s retirement.

Mr. Tanzberger has been the Senior Vice President and Chief Financial Officer of Service Corporation International (“SCI”) since in June 2006. Mr. Tanzberger joined SCI in August 1996 and held various management positions prior to being promoted to Corporate Controller in August 2002. He also held the position of Treasurer from 2007 until 2017. Before joining SCI, Mr. Tanzberger served as Assistant Corporate Controller at Kirby Marine Transportation Corp., an inland waterway barge and tanker company. He also served at Coopers and Lybrand LLP. Mr. Tanzberger is also a member of the Executive Committee of the Business Council of New Orleans and also serves on the Board of Directors of New Orleans Medical Mission Services, and Junior Achievement of Southeast Texas. Additionally, he is a member of the Board of Trustees for the United Way of Greater Houston, and the National Funeral Directors Association Funeral Service Foundation. Mr. Tanzberger holds a Bachelor of Business Administration from the University of Notre Dame.

Mr. Tanzberger has been appointed to serve as the chairman of the audit committee of the Board, effective as of the Effective Date. Mr. Tanzberger will be entitled to participate in the Company’s compensation policy for non-employee directors, which the Board currently expects will consist of annual grants of restricted stock having annual vesting restrictions based on compensation generally valued at $90,000 per year.

Item 7.01 Regulation FD Disclosure.

On December 22, 2021, the Company issued a press release announcing the resignation of Mr. Carmena from the Company’s Board and as the Company’s Principal Executive Officer, and the appointment of Mr. Tanzberger to the Board. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section. Further, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
10.1	Retirement Agreement, dated December 22, 2021, between Sanara MedTech Inc. and J. Michael Carmena.
99.1	Press Release, dated December 22, 2021 (furnished pursuant to Item 7.01).
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Sanara MedTech Inc.
Date:	December 22, 2021	By:	/s/ Michael D. McNeil
		Name:	Michael D. McNeil
		Title:	Chief Financial Officer

EX-10.1

Exhibit 10.1

RETIREMENT AGREEMENT

THIS RETIREMENT AGREEMENT (the “Agreement”) is dated effective as of December 22, 2021 (the “Effective Date”) between J. MICHAEL CARMENA (“Carmena”) and SANARA MEDTECH INC. (“Sanara”). Carmena and Sanara are sometimes hereinafter referred to individually as a “Party” and together as the “Parties”.

WHEREAS, Carmena is currently an employee of Sanara and serves as Vice Chairman of the Board of Directors of Sanara (the “Board”); and

WHEREAS, Carmena also serves as a manager, director, officer and/or employee of various affiliated entities of Sanara (“Affiliates”); and

WHEREAS, (i) Carmena was granted a total of 17,249 shares of Sanara common stock (“Sanara Stock”) pursuant to those certain two Restricted Stock Agreements each dated February 24, 2020, 7,482 of which shares of Sanara Stock are vested; and 5,750 of which shares of Sanara Stock will be vested January 1, 2022, (the existing stock grants referred to herein as the “Carmena Stock Grants”), all such Carmena Stock Grants were made pursuant to Sanara’s Restated 2014 Omnibus Long Term Incentive Plan dated February 10, 2020 (the “LTIP”); and

WHEREAS, Carmena was given options to purchase 500,000 shares of Sanara Stock (the “Carmena Options”) pursuant to that certain Warrant To Purchase Shares of Common Stock dated December 31, 2017 (the “Warrant”); and

WHEREAS, the number of shares granted to Carmena in the Warrant are now 5,000 following a reverse stock split of 1 for 100 shares in 2019 (the “Stock Split”); and

WHEREAS, Carmena will resign from the Board effective December 31, 2021 and retire from his position at Sanara and all Affiliates effective January 3, 2022 and in connection therewith the Parties desire to set forth certain agreements between them;

NOW, THEREFORE, for and in consideration of the premises herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1. Retirement; Resignation. Effective as of December 31, 2021 (the “Resignation Date”), Carmena shall resign as an officer of Sanara and all of its Affiliates including the Principal Executive Officer and as a director of Sanara and all its Affiliates including Vice Chairman of the Board (the “Resignation”). Effective as of January 3, 2022 (the “Retirement Date”) Carmena will resign as a manager and employee of Sanara and all its Affiliates (the “Retirement”).

2. Vesting of Carmena Stock Grants. In connection with the Resignation and the Retirement, Sanara shall (i) waive all vesting requirements and forfeiture provisions of the LTIP pertaining to the Carmena Stock Grants, all of which shall be automatically fully vested on the Retirement Date (the “Vesting Acceleration”); and (ii) all forfeiture provisions of the LTIP related to the Carmena Stock Grants. For the avoidance of doubt, the remaining number of shares which will vest under this provision is 4,017.

3. Other Provisions of the LTIP. Other than as expressly set forth in Section 2 above, the provisions contained in the LTIP that apply to the Carmena Stock Grants shall remain in full force and effect in accordance with their terms.

4. Carmena Options. The terms and provisions of the Warrant related to the exercise of the Carmena Options shall remain in full force and effect in accordance with their terms, as amended by the Stock Split.

5. Retirement Bonus. In connection with the Resignation and Retirement, Carmena will receive a one-time cash payment of $75,000 to be paid no later than January 15, 2022. Such payment shall be net of all federal tax deductions required to be withheld by employers.

6. Retirement Stock Grant. Carmena will be granted an additional 3,549 shares of Sanara Stock that will vest on the Retirement Date.

7. Forfeiture of Shares to Meet Carmena’s Tax Withholding Obligations. Sanara shall obtain the approval of the Board to consent to the forfeiture by Carmena to Sanara the number of shares of Sanara Stock having an aggregate fair value that equals the required tax withholding payment owed by Carmena upon the vesting of Sanara Stock in January 2022.

8. Restrictive Covenants. In exchange for the Vesting Acceleration and Sanara’s waiver of the forfeiture provisions of the LTIP, the Retirement Bonus, and the Retirement Stock Grant Carmena agrees that, for the remainder of his employment term and for a period of two (2) years following the Retirement Date, as follows:

(a) Agreement Not to Compete. For himself, or as a shareholder, owner, partner, joint venturer, promoter, consultant, manager, independent contractor, agent, or in some similar capacity, participate in a Competing Business (as defined below) within the Territory (as defined below).

(b) Agreement Not to Solicit Customers to Divert Business. On his own behalf or in the service of or on behalf of others, solicit or attempt to divert Business to a Competing Business or to any third party any Person, concern, or entity who is or was, or in the future will be (at the time of solicitation), a Customer of the Business or of Sanara (or any Customer of any of the foregoing) whether within or without the Territory, and further, Carmena will not, either directly or indirectly through any Family Member or any other Person, on his own behalf or in the service of or on behalf of others, initiate a call upon any Person, concern or entity who is, or was, or in the future will be (at the time of solicitation), a Customer of the Business or of Sanara for the purpose of diverting or appropriating business to a Competing Business, and further, if any such Customers initiate a call upon Carmena, then Carmena shall not entertain any such call without first referring such Person to Sanara.

(c) Agreement Not to Solicit Employees and Contractors. On his own behalf or in the service of or on behalf of others, solicit, divert, or recruit any employee or contractor of Sanara to leave such employment or contractual relationship, otherwise terminate his or her employment or contractual relationship, whether or not such employment or contractual relationship is pursuant to a written contract or at will.

(d) Agreement Not to Disparage Sanara. Not intentionally, knowingly or recklessly disparage Sanara, its products and services, its managers or any of their respective Affiliates or any of their respective managers, directors, officers, employees or other representatives, whether orally, in writing or otherwise, at any time.

2

(e) Definitions.

(i) “Business” means providing, selling, or manufacturing wound and skin care and soft tissue repair related products of the type or nature of those provided, sold or manufactured by the Company or providing or enabling wound care diagnostics or virtual/telemedicine wound care services such as those provided by the Company. In addition, Business shall include any other business that Sanara enters into during the two (2) year period following the Retirement Date.

(ii) “Competing Business” means any person, concern or entity which is engaged in, and to the extent engaged in, a business that is wholly or partially the same as the Business.

(iii) “Customer” means a person or entity which sells to, and/or buys from the Business, Sanara or the Affiliates.

(iv) “Family Member” means the spouse or legally adopted or natural-born descendants of whatsoever generation of Carmena or a trust for the benefit of any such persons, or any entity in which owns a material interest.

(v) “Territory” means the United States.

(f) Acknowledgment of Enforceability. Carmena expressly acknowledges and agrees that Carmena’s experience and abilities are such that Carmena’s observance of the covenants and restrictive agreements contained herein are reasonable as to scope, location and duration and that such observation shall not cause Carmena any undue hardship or unreasonably interfere with Carmena’s ability to earn a livelihood. Carmena has been provided with an opportunity to consult with legal counsel of Carmena’s selection for the meaning of the covenants and restrictions, which have been explained to Carmena’s satisfaction. Carmena hereby agrees that the limitations set forth above are reasonable and necessary for the protection of the Business, Sanara and the Affiliates. In this regard, Carmena specifically agrees that such limitation as to the period of time, geographic area and types and scope of restrictions on his activities are reasonable and necessary to protect the goodwill and other business interests of the Business, Sanara and the Affiliates.

(g) Revision. It is mutually understood and agreed that if any of the provisions relating to the scope, time, or territory of this Agreement are more extensive than is enforceable under applicable laws or are broader than necessary to protect the goodwill and legitimate business interests of the Business, Sanara and/or the Affiliates, then the Parties agree that they will reduce the degree and extent of such provisions by whatever minimal amount is necessary to bring such provisions within the ambit of enforceability under applicable law.

3

(h) Remedies. The invalidity or non-enforceability of this Section in any respect shall not affect the validity or enforceability of any other provisions of this Agreement. The Parties agree that the limitations contained in this Section with respect to time, geographical area and scope of activity are reasonable. In the event that any provision of this Section shall be held invalid or unenforceable by a court of competent jurisdiction by reason of the geographic or business scope or the duration thereof, such invalidity or unenforceability shall attach only to the scope or duration of such provision and shall not affect or render invalid or unenforceable any other provision of this Agreement, and, to the fullest extent permitted by law, this Agreement shall be construed as if the geographic or business scope or the duration of such provision had been more narrowly drafted so as not to be invalid or unenforceable. Carmena acknowledges that Sanara’s remedy at law for any breach or threatened breach of the provisions of this Section may be insufficient and may be inadequate and that Sanara shall be entitled to equitable relief, including by way of temporary and permanent injunction, without any requirement to post bond or other security therefor, in addition to any remedies Sanara may have at law.

9. Governing Law; Venue. This Agreement shall be governed by and construed, interpreted and enforced in accordance with the internal, substantive laws of the State of Texas, without giving effect to conflicts of laws principles. The Parties voluntarily and irrevocably submit to the jurisdiction of the courts of the State of Texas located in Tarrant County, Texas, and the Federal Courts of the United States of America located in Tarrant County, Texas, over any dispute between or among the Parties related to or arising out of this Agreement, and each Party irrevocably agrees that all such claims in respect of such dispute shall be heard and determined exclusively in such courts. The Parties hereby irrevocably consent to the jurisdiction of such courts and hereby waive, to the fullest extent permitted by law, any objection which they may now or hereafter have to the venue of such dispute related to or arising out of this Agreement brought in such court or any defense of inconvenient forum for the maintenance of such dispute. Each Party agrees that a judgment in any such dispute may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.

10. Assignment. This Agreement may not be transferred, assigned, pledged or hypothecated by either Party, whether by operation of law or otherwise, without the prior written consent of the non-assigning Party. This Agreement will be binding upon and will inure to the benefit of the Parties and their respective heirs, executors, administrators, successors and permitted assigns.

11. Counterparts. This Agreement may be executed in any number of counterparts (including by electronic delivery of signed signature pages) and by different Parties in separate counterparts, each of which counterparts, when so executed and delivered, will be deemed to be an original and all of which counterparts, taken together, will constitute but one and the same agreement.

12. Entire Agreement. This Agreement, including the other instruments and agreements contemplated herein and the other documents referred to herein, contains the entire understanding of the Parties with respect to the subject matter contained herein and therein. This Agreement supersedes all prior agreements and understandings among the Parties with respect to such subject matter.

13. Amendments. This Agreement may not be amended, modified or supplemented orally, but only by an agreement in writing signed by the Parties.

14. Severability. If any provisions contained in this Agreement shall for any reason be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not invalidate the entire Agreement. Instead, such provision shall be deemed to be modified to the extent necessary to render it valid and enforceable and if no such modification shall render it valid and enforceable then this Agreement shall be construed as if not containing such provision.

15. Drafting. The Parties acknowledge that each Party was actively involved in the negotiation and drafting of this Agreement and that no law or rule of construction shall be raised or used in which the provisions of this Agreement shall be construed in favor or against either Party hereto because one is deemed to be the author thereof.

16. COUNSEL. CARMENA ACKNOWLEDGES THAT HE IS EXECUTING A LEGAL DOCUMENT THAT CONTAINS CERTAIN DUTIES, OBLIGATIONS AND RESTRICTIONS AS SPECIFIED HEREIN. CARMENA FURTHERMORE ACKNOWLEDGES THAT HE HAS BEEN ADVISED OF HIS RIGHT TO RETAIN LEGAL COUNSEL, AND THAT HE HAS EITHER BEEN REPRESENTED BY LEGAL COUNSEL PRIOR TO HIS EXECUTION HEREOF OR HAS KNOWINGLY ELECTED NOT TO BE SO REPRESENTED.

17. Waiver. No delay by any Party in the exercise of any right under this Agreement shall waive such rights. Any waiver, to be enforceable, must be in writing.

18. Prevailing Party. If any legal action or other proceeding is brought for the enforcement of this Agreement or any document executed in connection with, or because of an alleged dispute, breach, default or misrepresentation in connection with any of the provisions of this Agreement or any document, instrument or agreement executed in connection herewith, the successful prevailing Party shall be entitled to recover reasonable attorney’s fees, court costs and all other costs and expenses incurred in that action or proceeding.

SIGNATURE PAGE FOLLOWS

4

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the day and year first above written.

SANARA:

/s/ Michael McNeil

Michael D. McNeil, Chief Financial Officer

Sanara MedTech Inc.

CARMENA:

/s/ J. Michael Carmena

J. Michael Carmena

5

EX-99.1

Exhibit 99.1

Sanara MedTech Inc. Announces the Retirement of J. Michael Carmena and Appointment of Eric Tanzberger to its Board of Directors

FORT WORTH, TX / December 22, 2021 / Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that J. Michael (“Mike”) Carmena will step down from the Company’s Board of Directors (the “Board”) and resign as the Company’s Principal Executive Officer, effective December 31, 2021 and Eric Tanzberger has been appointed to the Company’s Board effective January 1, 2022. Concurrently with his appointment to the Board, Mr. Tanzberger was appointed Chair of the Audit Committee.

Ron Nixon, Sanara’s Executive Chairman, stated, “Mike was a key leader at Sanara who led the building of the Company’s foundation. During his time as CEO and later as Vice Chairman, he has mentored our leadership team during the growth of our surgical business and the execution of our strategy. Speaking for the entire Board, we are grateful for his service to the Company and wish him the very best in retirement.”

“Eric Tanzberger is another outstanding addition to our Board. He has significant experience in finance, strategy, and corporate governance and will provide a unique perspective to the Board as the Company continues its strategic growth and expansion initiatives for the comprehensive wound and skin care strategy.”

Mr. Tanzberger is the Senior Vice President and Chief Financial Officer of Service Corporation International (“SCI”), the country’s leading provider of funeral, cremation, and cemetery services.

Mr. Tanzberger was appointed Senior Vice President and Chief Financial Officer in June 2006. He joined SCI in August 1996 and held various management positions prior to being promoted to Corporate Controller in August 2002. He also held the position of Treasurer from 2007 until 2017.

Before joining SCI, Mr. Tanzberger served as Assistant Corporate Controller at Kirby Marine Transportation Corp., an inland waterway barge and tanker company. Mr. Tanzberger also served at Coopers & Lybrand LLP and holds a Bachelor of Business Administration from the University of Notre Dame.

Mr. Tanzberger is currently a member of the Executive Committee and Audit Committee Chair of the United Way of Greater Houston. Additionally, he is a member of the Board of Trustees of Junior Achievement of Southeast Texas, and the National Funeral Directors Association Funeral Service Foundation.

About Sanara MedTech Inc.

With a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets, distributes, and develops wound and skincare products for use by physicians and clinicians in hospitals, clinics, and all post-acute care settings and is seeking to offer wound care and dermatology virtual consultation services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX^® Surgical Activated Collagen^®, FORTIFY TRG^™ Tissue Repair Graft and FORTIFY FLOWABLE^™ Extracellular Matrix to the surgical markets as well as the following products to the wound care market: BIAKŌS^™ Antimicrobial Skin and Wound Cleanser, BIAKŌS^™ Antimicrobial Wound Gel, BIAKŌS^™ Antimicrobial Skin and Wound Irrigation Solution and HYCOL^™ Hydrolyzed Collagen. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement, and cell compatible substrates. The Company believes it has acquired the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skincare for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of the healthcare industry. For more information, visit SanaraMedTech.com.

Information about Forward-Looking Statements

The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “anticipate,” “believes,” “contemplates,” “continue” “could,” “estimates,” “expect,” “intend,” “may,” “plan,” “potential” “predicts,” “preliminary,” “project,” “seek,” “should,” “target,” “will,” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the development of new products and expansion of the Company’s business in telehealth and wound care. These items involve risks, contingencies and uncertainties such as Sanara’s ability to retain key employees, uncertainties associated with the development and process for obtaining regulatory approval for new products, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.

All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.

Investor Contact:

Callon Nichols, Director of Investor Relations

713-826-0524

CNichols@sanaramedtech.com

SOURCE: Sanara MedTech Inc.

XML

Cover	Dec. 16, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 16, 2021
Entity File Number	001-39678
Entity Registrant Name	SANARA MEDTECH INC.
Entity Central Index Key	0000714256
Entity Tax Identification Number	59-2219994
Entity Incorporation, State or Country Code	TX
Entity Address, Address Line One	1200 Summit Avenue
Entity Address, Address Line Two	Suite 414
Entity Address, City or Town	Fort Worth
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	76102
City Area Code	(817)
Local Phone Number	529-2300
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	SMTI
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false